Related Experiment Video

Updated: May 28, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

Is iNOS beginning to smoke?

Carl Nathan1

  • 1Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA. cnathan@med.cornell.edu

Cell
|October 18, 2011
PubMed

Insights

Inhibiting inducible nitric oxide synthase (iNOS) may be a viable therapeutic strategy for treating chronic obstructive pulmonary disease, a leading cause of death worldwide.

Area of Science:

  • Biomedical Research
  • Pulmonary Medicine
  • Inflammation

Background:

  • Inducible nitric oxide synthase (iNOS) plays a significant role in various inflammatory conditions.
  • Despite its involvement in inflammation, therapeutic inhibition of iNOS has not yet achieved success.
  • Chronic obstructive pulmonary disease (COPD) is a major global health concern and a leading cause of mortality.

Discussion:

  • Seimetz et al. (2011) present a compelling argument for targeting iNOS in COPD treatment.
  • This strategy focuses on mitigating the inflammatory processes central to COPD pathogenesis.
  • The study explores the potential of iNOS inhibition as a viable therapeutic avenue.

Key Insights:

  • iNOS plays a critical role in the inflammatory pathways of COPD.
  • Targeting iNOS offers a potential new therapeutic direction for COPD management.
  • Overcoming previous hurdles in iNOS inhibition is key to realizing its therapeutic potential.

Outlook:

  • Further research is warranted to develop effective iNOS inhibitors for COPD.
  • Successful iNOS inhibition could lead to novel treatments for this debilitating disease.
  • This approach may pave the way for managing other iNOS-driven inflammatory disorders.

More Related Videos

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface10:47

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface

Published on: February 21, 2011

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...